How simpler implementations enable complex cell and gene therapies
After spending 12 years working in the biopharmaceutical industry – three of those here at Vineti – I’ve learned first-hand that cell and gene therapies…
New FDA guidance: cell therapies and patient identifiers
When the US Food and Drug Administration (FDA) recently made two draft guidance documents for the cell and gene therapies available for comment, the Vineti…
Cell and gene therapies: the necessity of a purpose-built platform
Given the wide array of CRMs and other digital systems already serving healthcare and biopharma, that reality might sound like overkill. But after more than…
Preparing for Cell and Gene Therapy 3.0
Patient data is mission-critical data — especially in cell and gene therapy.
In cell and gene therapy (CGT), the patient is the process is the…
Patient data – the unique role in cell and gene therapies (CGTs)
Patient data is mission-critical data — especially in cell and gene therapy.
In cell and gene therapy (CGT), the patient is the process is the…
Patient data – why it is critical for cell and gene therapy stakeholders
The first blog post in this series provided an overview of how the advanced therapies supply chain is different from traditional and biologic drug products…
Patient data – unique challenges, critical uses in the cell therapy value chain
The previous two blog posts in this series provided an overview of why patient-related data matters in cell therapy and gene therapy (CGTs), and how…
Integrated patient data – the future of advanced therapies
The cell and gene therapy (CGT) sector is poised for exponential growth — which will come in novel ways that reflect the unique nature of…
Lykan Bioscience and Vineti Announce Partnership to Advance Cell-based Therapies from Clinical to Commercialization
Lykan Bioscience’s world-class manufacturing capabilities, integrated with Vineti’s leading digital enterprise platform for cell and gene therapy supply chains, will streamline process development and manufacturing…
Vineti announces agreement with Imvax to utilize Vineti’s PTM Essentials™ solution
Vineti’s enterprise technology will enable critical patient-specific Chain of Custody management for Imvax, supporting Imvax’s goal of reaching more patients as fast as possible
Building CGT’s Clinical Trial Potential: PRA’s Partnership with Cell and Gene Therapy Supply Chain Software Leader Vineti
Key Highlights: PRA’s partnership with Vineti will optimize clinical trial delivery, clinical study operations and data management, and commercialization readiness...
PRA Health Sciences Announces Partnership with Vineti
RALEIGH, NC and SAN FRANCISCO, CA, June 15, 2021 — PRA Health Sciences and Vineti, Inc., today announced a new...